Sign in

ALZN on Nasdaq

Alzamend Neuro, Inc.

Alzamend Neuro, Inc. is an American pharmaceutical preparations company based in Atlanta.2 Its shares trade on Nasdaq under the symbol ALZN.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$8.8MNet income, fiscal 20263

Compare with another stock.

  • TickerALZN on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersAtlanta, United States2
  • Incorporated inDE4
  • Business address480 Peachtree Road Ne, Second Floor, Suite 103, Atlanta, Ga 303264
  • Filer category, Emerging growth company4
  • Legal formCorporation2
  • LEI549300W6G6EUO4ZRIB822
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Corporation Service Company, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 59760732

See how the biggest companies compare on our leaderboards

III clinical trials in humans, we intend to seek approval to commercialize ALZN002 through a Biologics License Application (“BLA”);5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

-1196.4%Return on equity3

Financial statements

Operating income6789103-$8.8M in 2026+98% since 2020
-$15.0M-$10.0M-$5.0M02020: -$4.4M-$4.4M20202021: -$5.0M-$5.0M2021+12%2022: -$12.3M-$12.3M2022+149%2023: -$14.9M-$14.9M2023+21%2024: -$9.9M-$9.9M2024−33%2025: -$4.5M-$4.5M2025−55%2026: -$8.8M-$8.8M2026+95%
Net income6789103-$8.8M in 2026+99% since 2020
-$15.0M-$10.0M-$5.0M02020: -$4.4M-$4.4M20202021: -$5.0M-$5.0M2021+14%2022: -$12.4M-$12.4M2022+145%2023: -$14.9M-$14.9M2023+20%2024: -$9.9M-$9.9M2024−33%2025: -$4.5M-$4.5M2025−55%2026: -$8.8M-$8.8M2026+94%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2026-04-302025-04-30
Research and development$3.6M$1.4M
General and administrative$5.1M$3.1M
Total operating expenses$8.8M$4.5M
Loss from operations-$8.8M-$4.5M
Interest income$1.1K
Interest expense-$6.6K-$18.0K
Total other expense, net-$5.5K-$18.0K
NET LOSS-$8.8M-$4.5M
Dividends on preferred shares-$117.0K
Deemed dividend on warrant modification issued with preferred shares-$473.2K
NET LOSS AVAILABLE TO COMMON SHARES-$8.8M-$5.1M
Basic net loss per common share-$2.63-$11.32
Diluted net loss per common share-$2.63-$11.32
Basic weighted average common shares outstanding3.3M shares450.8K shares
Diluted weighted average common shares outstanding3.3M shares450.8K shares

Compare Alzamend Neuro, Inc. with another company

Corporate structure

Alzamend Neuro, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Alzamend Neuro, Inc.

  • Milton C. Ault Iii. Filed SCHEDULE 13D/A on Alzamend Neuro, Inc., latest Oct 7, 2025 (10 filings since Apr 28, 2022)
  • Alzamend Neuro, Inc. Atlanta, Georgia, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Alzamend Neuro, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$314.9K3 Apr 30, 2026$425.6K3 Apr 30, 2025−26.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$710.7K3 Apr 30, 2026$3.9M3 Apr 30, 2025−82.0%

Properties, in its own words

Our executive office utilizes approximately 150 square feet of leased office space at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326. The lease for our Georgia offices expires in December 2026. The annual base rent under the lease, payable on a monthly basis, was approximately $36,000 during the fiscal year ended April 30, 2026.

Our accounting and finance office is located in Orange County, California utilizing approximately 200 square feet of shared office space within the offices of HDI, a related party. Our legal office is located in New York, NY utilizing shared office space within the offices of HDI. We currently do not pay rent for our Orange County, California or New York, NY office spaces. We believe our present space is adequate for our current operations.

Item 2 of the 10-K filed Jul 22, 2026.5

Leadership

Who has led Alzamend Neuro, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephan Jackman2021–now

Chief financial officer

  1. Escalona Lien2021
  2. David J. Katzoff2022–now

Chief operating officer

  1. David J. Katzoff2021
2025
Board members and other officers (10)

Timeline

  1. Sep 29, 20268-K Regulation FD disclosure26
  2. Aug 3, 20268-K Entered a material agreement; Listing notice or transfer; Unregistered sale of shares27
  3. Jul 21, 20268-K Other events28
  4. Apr 17, 20268-K Shareholder vote29
  5. Mar 20, 20268-K Listing notice or transfer30
  6. Mar 6, 20268-K Entered a material agreement31
  7. Nov 18, 20258-K Other events32
  8. Oct 14, 20258-K Bylaws or fiscal year changed33
  9. Oct 9, 20258-K Unregistered sale of shares34
  10. Sep 25, 20258-K Unregistered sale of shares35
  11. Aug 1, 20258-K Unregistered sale of shares36
  12. Jul 23, 20258-K Results of operations37
  13. Jun 14, 2021New chief executive Stephan Jackman becomes CEO14
  14. Feb 25, 2016Founded Alzamend Neuro, Inc. is founded2

Calendar

Coming up

  1. Dec 8, 2026Reports results for the quarter ending Oct/2026 A year earlier it reported ($0.30) a share, on Dec 9, 2025.38

When it reported results

  1. Jul 23, 2025Reported quarterly or annual results37
  2. Dec 12, 2024Reported quarterly or annual results39
  3. Mar 16, 2023Reported quarterly or annual results40

Drug trials and FDA: coming up

  1. Dec 2026Phase 1/2 trial readout expected Phase 1/2 trial of AL001 and Lithium carbonate in Bipolar I Disorder: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07540338).41

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

275 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 131 insider forms, 10 large holders, 49 other. The latest 20:

  1. Oct 9, 2026RW EDGAR
  2. Sep 29, 20268-K EDGAR
  3. Sep 10, 202610-Q EDGAR
  4. Aug 31, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 31, 20264/A PRIMARY DOCUMENT EDGAR
  6. Aug 31, 20264/A PRIMARY DOCUMENT EDGAR
  7. Aug 28, 2026PRE 14A EDGAR
  8. Aug 21, 2026S-1 EDGAR
  9. Aug 20, 20264/A PRIMARY DOCUMENT EDGAR
  10. Aug 20, 20263/A PRIMARY DOCUMENT EDGAR
  11. Aug 4, 20264 PRIMARY DOCUMENT EDGAR
  12. Aug 4, 20263 PRIMARY DOCUMENT EDGAR
  13. Aug 4, 20264 PRIMARY DOCUMENT EDGAR
  14. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  15. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  16. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  17. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  18. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  19. Aug 4, 20265 PRIMARY DOCUMENT EDGAR
  20. Aug 4, 20265 PRIMARY DOCUMENT EDGAR

The 275 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

114 open-market trades by officers, directors and large owners since October 2021: 82 buys and 32 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2026AULT MILTON C IIIDirectorSale2,000$1.56$3.1KForm 4
Apr 14, 2026AULT MILTON C IIIDirectorBuy110,388$1.00$110.4KForm 4
Apr 14, 2026AULT MILTON C IIIDirectorBuy110,388$1.00$110.4KForm 4
Apr 14, 2026AULT MILTON C IIIDirectorBuy108,388$1.00$108.4KForm 4
Dec 23, 2025AULT MILTON C IIIDirectorSale1,851$2.07$3.8KForm 4
Dec 19, 2025Horne William B.DirectorSale3,333$2.12$7.1KForm 4
Oct 23, 2025McGrath Lynne FaheyDirectorSale30$2.29$69Form 4
Oct 9, 2025AULT MILTON C IIIDirectorSale20,397$2.32$47.3KForm 4
Oct 8, 2025AULT MILTON C IIIDirectorSale101,394$2.44$247.4KForm 4
Oct 7, 2025AULT MILTON C IIIDirectorSale57,379$2.49$142.9KForm 4
Oct 6, 2025AULT MILTON C IIIDirectorSale82,033$2.45$201.0KForm 4
Oct 3, 2025AULT MILTON C IIIDirectorSale65,903$2.44$160.8KForm 4
Oct 2, 2025AULT MILTON C IIIDirectorSale20,686$2.39$49.4KForm 4
Oct 1, 2025AULT MILTON C IIIDirectorSale36,777$2.35$86.4KForm 4
Sep 30, 2025AULT MILTON C IIIDirectorSale3,566$2.33$8.3KForm 4
Sep 29, 2025AULT MILTON C IIIDirectorSale38,324$2.31$88.5KForm 4
Sep 26, 2025AULT MILTON C IIIDirectorSale37,738$2.31$87.2KForm 4
Sep 25, 2025AULT MILTON C IIIDirectorSale14,628$2.31$33.8KForm 4
Sep 24, 2025AULT MILTON C IIIDirectorSale39,140$2.31$90.4KForm 4
Sep 23, 2025AULT MILTON C IIIDirectorSale43,238$2.38$102.9KForm 4

All 114 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Stephan S. Jackman50$350.0K$468.3K43
2025David J. Katzoff64$150.0K43
2024Chief Executive Officer$350.0K$443.6K43
2024Chief Financial Officer$150.0K43

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Kingsbury Capital Investment Advisors LLC1,329,100$1.6M1.3%+762,367
Kmt Wealth Management, LLC1,329,100$1.6M1.3%New
Geode Capital Management, LLC26,371$31.6K0.0%−19,309
Vanguard Fiduciary Trust Co21,020$25.2K0.0%No change
Vanguard Capital Management LLC7,556$9.1K0.0%+3,156
Tower Research Capital LLC (TRC)3,517$4.2K0.0%−2,667
UBS Group AG2,352$2.8K0.0%−2,152
BlackRock, Inc.437$5240.0%No change
IFG Advisory, LLC22$260.0%New
SBI Securities Co., Ltd.22$260.0%No change
Caitong International Asset Management Co., Ltd3$40.0%−1
Harbor Investment Advisory, LLC1$10.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Alzamend Neuro, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAlzamend Neuro, Inc.1
  • CIK0001677077
  • Employer ID (EIN)81-18229095
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsApril 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address480 Peachtree Road Ne, Second Floor, Suite 103, Atlanta, GA 303261
  • Phone844-722-63331
  • Shares outstanding4,825,723 as of Sep 10, 202613
  • Public float$9.6M as of Oct 31, 20255
  • AuditorHASKELL & WHITE LLP, Irvine, California PCAOB ID 200; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJun 22, 20161
  • Filings397 in all: 4 (144), 8-K (69), CORRESP (19), 10-Q (16), 3 (12), UPLOAD (12), 1-U (9), 5 (8)1
    All 49 form types

    S-1/A (7), 10-K (6), DEF 14A (6), DEFA14A (6), PRE 14A (6), SCHEDULE 13D/A (6), 1-SA (5), 4/A (5), 424B5 (5), SC 13D/A (5), 1-K (4), EFFECT (4), 1-A/A (3), D (3), S-1 (3), 1-A (2), 424B3 (2), 8-K/A (2), DOS/A (2), DOSLTR (2), DRSLTR (2), FWP (2), S-3 (2), 1-A-W (1), 1-SA/A (1), 1-U/A (1), 144 (1), 144/A (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), DOS (1), DRS (1), DRS/A (1), NT 10-K (1), NT 10-Q (1), QUALIF (1), RW (1), S-8 (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Jul 22, 2026
    Quarterly report (10-Q) Sep 10, 2026
    Proxy statement (DEF 14A) Feb 26, 2026
    Latest 8-K (8-K) Sep 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareALZNNASDAQ

From the cover page of the 10-K filed Jul 22, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Alzamend Neuro, Inc. names in Item 1A of its 10-K filed Jul 22, 2026: 53 risks under these headings, as written.5

  • Risks Related to Our Company, Early Stage of Clinical Development and Financial Condition
  • We need to obtain substantial additional funding to complete the development and any commercialization of AL001 and ALZN002. If we are unable to raise this capital when needed, we may be forced to delay, reduce or eliminate our research and development programs and other operations.
  • Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
  • We are at an early stage of clinical development and currently have no source of near-term revenue and may never become profitable.
  • Risks Related to Our Product Candidates
  • We have both operational and financial milestones that must be met to maintain the licensing rights to our current technology and intellectual property from the Licensor.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with the Licensor, we could lose license rights that are critical to our business.
  • We are substantially dependent on the success of our product candidates, which may not receive regulatory approval or be successfully commercialized.
  • AL001 and ALZN002 may not achieve market acceptance, which would significantly limit our ability to generate revenue.
  • Problems in the manufacturing process, failure to comply with manufacturing regulations or unexpected increases in manufacturing costs could harm our business, results of operations and financial condition.
  • Serious adverse events or other safety risks could require us to abandon development and preclude, delay or limit approval of AL001 or ALZN002, or limit the scope of any approved label or market acceptance.
  • If we fail to obtain and sustain an adequate level of reimbursement for our products by third-party payers, sales and profitability will be adversely affected.
The other 43 risks
  • Risks Related to Development and Regulatory Approval of Our Drug Candidates
  • We rely on third parties to conduct our preclinical and clinical studies and perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our medicines and drug candidates and our business could be substantially harmed.
  • The regulatory approval process is uncertain, requires us to utilize significant resources, and may prevent us or our future commercial partners from obtaining approvals for the commercialization of AL001 or ALZN002.
  • There is a high rate of failure for drug candidates proceeding through clinical trials.
  • Most attempts at drug approval for Alzheimer’s have failed.
  • Clinical trials for AL001 or ALZN002 can be expensive, time consuming, uncertain and susceptible to change, delay or termination.
  • If our products do not receive breakthrough therapy designation, it could potentially increase the FDA’s review time and adversely impact our development timeline. Even if the FDA grants breakthrough therapy designation, it does not guarantee faster product development or FDA review and does not necessarily increase the likelihood of the product candidates receiving approval from the FDA.
  • Even if we receive regulatory approval for any of our future product candidates, we will be subject to ongoing FDA and other regulatory body obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, will be subject to labeling and manufacturing requirements and could be subject to other restrictions. Failure to comply with these regulatory requirements or the occurrence of unanticipated problems with our products could result in significant penalties.
  • AL001 or ALZN002 and any of our future product candidates, if approved, may cause or contribute to adverse medical events that we are required to report to the FDA and regulatory authorities in other countries and, if we fail to do so, we could be subject to sanctions that would materially harm our business.
  • Legislative or regulatory reforms with respect to products may make it more difficult and costly for us to obtain regulatory clearance or approval of AL001, ALZN002 or any of our future product candidates and to produce, market, and distribute our products after clearance or approval is obtained.
  • Our ability to market AL001, ALZN002 and any future product candidates in the United States, if approved, will be limited to use for the treatment of the indications for which they are approved, and if we want to expand the indications for which we may market AL001, ALZN002 and any future product candidates, we will need to obtain additional FDA approvals, which may not be granted.
  • The anticipated development of a REMS for AL001 or ALZN002 could cause delays in the approval process and would add additional layers of regulatory requirements that could impact our ability to commercialize AL001 and ALZN002 in the United States and reduce their market potential.
  • If we are found in violation of “fraud and abuse” laws, we may be subject to criminal and civil penalties and/or be suspended or excluded from participation in government-run healthcare programs, which may adversely affect our business, financial condition and results of operations.
  • Risks Related to Our Business and Industry
  • If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop AL001, ALZN002 or any future product candidates, conduct our in-licensing and development efforts or commercialize AL001, ALZN002 or any of our future product candidates.
  • We expect to face substantial competition, with other entities possibly discovering, developing or commercializing products before, or more successfully than we do.
  • Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent our product candidates from being developed or commercialized in a timely manner, which could negatively impact our business.
  • Risks Related to Our Intellectual Property
  • We may be forced to litigate to enforce or defend our intellectual property rights, or the intellectual property rights of our licensors.
  • We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
  • We may become subject to third parties’ claims alleging infringement of patents and proprietary rights or seeking to invalidate our patents or proprietary rights, which would be costly, time-consuming and, if successfully asserted against us, delay or prevent the development and commercialization of AL001 or ALZN002.
  • If our efforts to protect the proprietary nature of our intellectual property related to AL001, ALZN002 or any of our potential future product candidates are not adequate, we may not be able to compete effectively in our market.
  • Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect AL001 and ALZN002.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with any of these requirements.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Risks Relating to Legal Matters
  • If product liability lawsuits are brought against us, we will incur substantial liabilities and may be required to limit the commercialization of AL001 or ALZN002.
  • Risks Relating to Ownership of Our Common Stock
  • We are not in compliance with the Nasdaq continued listing requirements. If we are unable to regain compliance with, or thereafter maintain compliance with, the continued listing requirements of The Nasdaq Capital Market, our Common Stock could be delisted, which would adversely affect our Common Stock’s market price and liquidity and reduce our ability to raise capital.
  • We do not know whether an active market will be sustained; as a result, it may be difficult for you to sell your shares of our common stock.
  • The market price of our common stock is volatile, which could result in substantial losses for investors.
  • If there are substantial sales of shares of our common stock, the price of our common stock could decline.
  • Our bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • Certain provisions of our certificate of incorporation allow concentration of voting power, which may, among other things, delay or frustrate the removal of incumbent directors or a takeover attempt, even if such events may be beneficial to our stockholders.
  • General Risk Factors
  • We must effectively manage the growth of our operations, or our Company will suffer.
  • We may not be successful in our efforts to expand our pipeline of product candidates.
  • We may experience product recalls or inventory losses caused by unforeseen events, cold chain interruption and testing difficulties.
  • Because we do not intend to pay dividends on our common stock, you must rely on stock appreciation for any return on your investment.
  • We have identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.
  • We may have trouble hiring additional qualified personnel.
  • Failure of our information technology systems could significantly disrupt the operation of our business.
  • We are subject to various claims and legal actions arising in the ordinary course of our business.
  • We will be subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our anticipated operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.
  • Certain provisions of our certificate of incorporation, bylaws and Delaware law make it more difficult for a third party to acquire us and make a takeover more difficult to complete, even if such a transaction were in the stockholders’ interest.
  • Failure to build our finance infrastructure and improve our accounting systems and controls could impair our ability to comply with the financial reporting and internal controls requirements for publicly traded companies.
  • If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our common stock could decline.
  • Our charter provides for limitations of director liability and indemnification of directors and officers and employees.
  • We could be subject to securities class action litigation.

Legal proceedings

We are subject to various claims and legal actions arising in the ordinary course of our business. Any such litigation could be very costly and could distract our management from focusing on operating our business. The existence of any such litigation could harm our business, results of operations and financial condition. Results of actual and potential litigation are inherently uncertain. An unfavorable result in a legal proceeding could adversely affect our reputation, financial condition and operating results. There are no legal proceedings or arbitration proceedings currently pending against our company.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43